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(n  39,530), three comparing Simvastatin (n  20,859) and three comparing Atorv-
astatin (n  15,553) versus control were retrieved. No head-to-head comparisons 
between these statins in the pre-deﬁned doses were found. All statins were signiﬁcantly 
superior to control in the evaluated outcomes, and the highest risk reductions observed 
were for non-fatal myocardial infarction (MI): Atorvastatin relative risk (RR)  0.57 
(95% CI: 0.44–0.74, I2  0%), Pravastatin RR  0.79 (95% CI: 0.73–0.86, I2  12%), 
 Simvastatin RR  0.62 (95% CI: 0.54–0.70, I2  0%). Indirect comparisons showed 
no statistically signiﬁcant difference between statins in the prevention of total death, 
CV death and stroke. When compared to Pravastatin, the RR of MI for Simvastatin 
was 0.78 (95% CI: 0.67–0.91) and for Atorvastatin was 0.71 (95% CI: 0.54–0.94); 
the comparison between Atorvastatin versus Simvastatin showed no difference (RR  
0.92, 95% CI: 0.68–1.29). CONCLUSIONS: Our results showed similar efﬁcacy 
among these statins in major events reduction in the doses evaluated. Pravastatin seems 
to be less effective than the others in the prevention of MIs. Considering the similar 
results of these drugs, market price must be used in the selection of the most appropri-
ate therapy.
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OBJECTIVES: This study compared blood pressure (BP) outcomes (changes in BP and 
goal attainment) in adult patients (age 18 years) treated with an ARB or ARB-HCTZ 
ﬁxed dose combination. METHODS: A retrospective study was conducted using the 
GE Centricity EMR database, which contains the ambulatory health records for more 
than 11 million US patients. Patients with a physician order for one of the following 
ARBs or ﬁxed-dose combination (FDC) with HCTZ (candesartan, irbesartan, losar-
tan, olmesartan or valsartan) prior to December 2007 were included in the study. 
Demographics, clinical characteristics (co-morbidities, previous antihypertensive medi-
cations) and BP readings at baseline and throughout the 13-month follow-up period 
were recorded. The mean change in systolic and diastolic BPs and percent patients 
attaining BP goal (two consecutive BP readings 140/90 or 130/80 in patients with 
diabetes or renal disease) were recorded. RESULTS: A total of 81,706 patients (60.5% 
female, mean age 61.6 years) receiving an ARB or ARB-HCTZ FDC were identiﬁed. 
Patients with prior antihypertensive medication usage [57,501 (70.4%)] had higher 
baseline BP readings [mean SBP (SD): 147.4 (29.35) vs. 138.7 (18.93) mmHg; mean 
DBP (SD): 84.2 (17.93) vs. 80.8 (12.35)] and also experienced greater reductions in 
BP [mean SBP change (SD): 21.1 (29.61) vs. 13.2 (17.31) mmHg]. At baseline, a 
greater proportion of patients with prior antihypertensive medication usage (57.8% 
vs. 49.5) were not at BP goal. BP goal attainment was similar between the two groups 
(60.6% vs. 62.6%, prior vs. absence, respectively). Mean time to goal (82.8 days vs. 
78.5 days, prior vs. absence, respectively) was also similar between the two groups. 
CONCLUSIONS: Most patients initiating ARB /ARB-HCTZ therapy have utilized 
other antihypertensive medications in the 13 months prior to starting ARBs. Prior 
antihypertensive medication users experienced greater reductions in BP. BP goal 
 attainment was similar between patients with and without prior antihypertensive 
medications.
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OBJECTIVES: Compare combined optimal lipid value (OLV) goal attainment [low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
C), and triglycerides (TG)] between patients initiating niacin extended-release [NER] 
 simvastatin (NER/S) and ezetimibe  simvastatin (E/S) combination therapies among 
patients in a managed care setting. METHODS: An observational cohort study of 
patients aged  18 initiating NER/S (addition of NER to existing simvastatin therapy) 
or E/S therapy between January 1, 2001 and June 30, 2006 (index date) was performed 
using the HealthCore Integrated Research Database. Patients with a minimum 24 
months of follow-up and diagnosis of cardiovascular disease during the 12 months 
prior to index date were included. A propensity score regression model for treatment 
selection was created after adjusting for age, gender, baseline LDL-C, HDL-C, and 
TG, and Deyo-Charlson comorbidity index (DCI) score. The propensity score was 
included in a multivariate logistic regression model to estimate combined OLV goal 
attainment (per treatment guidelines) between the groups. RESULTS: A total of 883 
patients were identiﬁed initiating NER/S (n  445) or E/S (n  438). E/S patients were 
younger (51.4 o 8.4 years vs. 54.0 o 8.5 years; p  0.001) and less likely to be male 
(55.3% vs. 81.1%; p  0.001). Fewer E/S patients were likely to have prior hyperten-
sion (67.1% vs. 80.2%; p  0.001) and congestive heart disease (17.1% vs. 45.6%; 
p  0.001) versus NER/S patients, though the pre-index DCI score was statistically 
non-signiﬁcant between the groups (0.7 o 1.1: E/S vs. 0.8 o 1.1: NER/S; p  0.097). 
Logistic regression showed that NER/S patients were 64% more likely to achieve 
combined OLV goal attainment as compared to E/S treated patients [Odds Ratio: 1.64 
(95% CI: 1.02—2.62); p  0.04]. CONCLUSIONS: NER/S treatment was associated 
with a likelihood of combined OLV goal attainment versus E/S patients. Further 
research on impact of early initiation of NER/S therapy emphasizing multiple lipid 
parameter management versus LDL-C-only focused treatment strategies comes is 
warranted.
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OBJECTIVES: 1) To compare antihypertensive efﬁcacy of Losartan and Irbesartan 
controlling for baseline Seated Diastolic and Systolic Blood Pressure (SeDBP&SeSBP) 
before treatments, and 2) to compare antihypertensive efﬁcacy of Losartan and 
 Irbesartan between gender controlling for 1) baseline SeDBP&SeSBP, and 2) age. 
METHODS: An experimental design was performed. All hypertensive patients who 
were prescribed 50 mg. Losartan once a day or 150 mg. Irbesartan once a day for 
hypertension during January 1-June 30, 2008 were the population framework. Exclu-
sion criteria included concomitant diseases that would present safety hazards and 
concomitant medications that might interfere with the assessment of efﬁcacy or safety 
e.g., drugs known to affect BP. Simple random technique was employed. The A 0.05, 
power 0.90 and effect size 0.07 were set to generate 200 samples in each group (total 
400). The average baseline SeDBP&SeSBP of Losartan group and Irbesartan group 
were 91.86 o 13.73, 150.76 o 19.14 and 89.56 o 10.69, 148.42 o 15.45 respectively. 
Baseline SeDBP&SeSBP were used as covariates. After medications for eight weeks 
SeDBP&SeSBP were measured and compared. RESULTS: Total 400 (100%) patients, 
mostly 267 (66.80%) were female, 133 (33.33%) were male with average age 63.31 
o 12.52 years. After treatment the average SeDBP of Losartan or Irbesartan groups 
were 77.26 o 9.76 and 74.43 o 9.84 mm. Hg respectively (p  .000, ANCOVA). After 
treatment the average SeSBP of Losartan or Irbesartan groups were 131.72 o 15.17 
and 127.50 o 12.22 mm. Hg respectively (p  .010, ANCOVA). When controlled age 
(covariate) and added gender (ﬁxed factor) to the model, the means of SeDBP&SeSBP 
of Losartan group and Irbesartan group were 77.26 o 9.76, 128.81 o 12.89 and 72.43 
o 9.84, 127.50 o 12.22 mm. Hg respectively (p  0.000 and 0.029, two way ANCOVA 
without gender interaction (p  0.520, 0.101). CONCLUSIONS: Irbesartan 150 mg. 
once a day could signiﬁcantly lower seated systolic and diastolic blood pressure in 
hypertension patients better than Losartan 50 mg. once a day. Gender made no dif-
ferences on efﬁcacy of the two drugs.
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OBJECTIVES: To compare the effectiveness of dual combinations of angiotensin II 
receptor blockers (ARBs) and ACE Inhibitors (ACEIs) with hydrochlorothiazide 
(HCTZ) or Calcium Channel Blockers (CCBs) in reaching target blood pressure (BP) 
in a real-world setting. METHODS: Records from a longitudinal population-based 
database of more than 170,000 patients in over 53 family practice clinics in south-
western Ontario, Canada were analyzed. These records contained chart-abstracted 
information such as visit diagnosis, BP, medications and consultation notes. The 
records from adult non-diabetic patients who were diagnosed with hypertension and 
were initiated on the combination therapy in 2005 and continued on the combination 
for at least 9 months were included. Hypertension was deﬁned as a BP exceeding 
140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive 
medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) 
were recorded and the combination of ARBsHCTZ was compared to other combina-
tions. Due to the well known comparable safety proﬁle of the compounds, a safety 
analysis was not performed. RESULTS: A total of 4,458 patients were treated with 
dual combinations of ARBs and ACEIs with HCTZ or CCBs. The proportions of 
patients reaching target BP were 35% on ARBs  HCTZ compared to 30% on 
ACEIsHCTZ (p  0.006), 32% on ARBsCCBs (p  0.03), and 28% on ACEIsCCBs 
(p  0.001). CONCLUSIONS: In the real-world setting, a greater proportion of 
hypertensive patients treated with the dual combination ARBHCTZ reached target 
BP than the dual combinations of ARBCCB, ACEIHCTZ, or ACECCB. Patients 
treated with the combination of an ARB with HCTZ or CCB achieved target BP in a 
greater proportion than patients treated with ACEI-based counterparts.
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BACKGROUND: The randomized double-blind parallel group trial, INPRACTICE, 
demonstrated a signiﬁcant beneﬁt of ezetimibe co-administration with simvastain 
10/40 mg in patients achieving LDL-C targets of 2 mmol/L, compared to atorvastatin 
